Sanofi Still Needs Fix For Adverse Event Reporting As FDA Seeks Retrospective Study, Pinches Accenture
Executive Summary
FDA's warning letter to Sanofi-Aventis US over the firm's failure to resolve problems that have delayed adverse event reporting shows the agency is emphasizing the issue in its compliance efforts – and becoming more pointed in its requests for fixes.
You may also be interested in...
Adverse Event Reports From Acorda Languished As Long As 100 Days, FDA Finds
FDA warning letter says the company did not report all complaints about the lack of efficacy of its muscular sclerosis drug Ampyra.
Warning Letter On Adverse Event Reporting May Stem As Much From Jazz Reaction As REMS Problem
Jazz Pharmaceuticals initially admitted it had known about 10 deaths and 64 other serious, unexpected adverse drug experiences associated with its cataplexy drug Xyrem, but later changed its story, FDA says.
Sanofi Lacks System To Prevent Microbial Contamination At Its German Plant, FDA Says
Sanofi-Aventis has not established or followed appropriate written procedures to prevent microbiological contamination of drug products at its manufacturing facility in Frankfurt, FDA told the company.